NanoViricides, Inc. NEW (NNVC): Price and Financial Metrics
NNVC Price/Volume Stats
| Current price | $1.10 | 52-week high | $2.00 |
| Prev. close | $1.11 | 52-week low | $1.00 |
| Day low | $1.10 | Volume | 5,600 |
| Day high | $1.13 | Avg. volume | 33,226 |
| 50-day MA | $1.21 | Dividend yield | N/A |
| 200-day MA | $1.24 | Market Cap | 12.96M |
NNVC Stock Price Chart Interactive Chart >
NanoViricides, Inc. NEW (NNVC) Company Bio
NanoViricides, Inc. is a biopharmaceutical company. The Company researches treatments for viruses such as AIDS/HIV, Hepatitis C, influenza, and Asian bird flu.
Latest NNVC News From Around the Web
Below are the latest news stories about NANOVIRICIDES INC that investors may wish to consider to help them evaluate NNVC as an investment opportunity.
NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share exciting updates on their antiviral drug candidate, NV 387. |
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricidesSHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Single-Ascending ... |
NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional ApplicationsSHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2023 with the Securities and Exchange ... |
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug DevelopmentSHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reports that its broad-spectrum antiviral ... |
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSVSHELTON, CT / ACCESSWIRE / October 16, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023 with the Securities and Exchange Commission (SEC) ... |
NNVC Price Returns
| 1-mo | N/A |
| 3-mo | -5.98% |
| 6-mo | -2.65% |
| 1-year | -17.29% |
| 3-year | -73.75% |
| 5-year | -78.12% |
| YTD | 7.84% |
| 2023 | -8.11% |
| 2022 | -70.16% |
| 2021 | 29.62% |
| 2020 | 14.34% |
| 2019 | -37.25% |
Loading social stream, please wait...